

Index

a

- Acanthaster planci* 316
 acetals 222–223, 227, 351, 352, 357
 acetate 222, 226, 228, 229
 Achmatowicz strategy 2–4
 ACHN-490 180–181
 acid labile 351, 352, 364
Aconitum carmichaeli 109
 activated ester 364
 AG-2 glycan 316–318
 aglycon moiety modifications 199–201
 alkylacylglycerols 335
 alkylglycerols 335
 alkyne 298, 299, 300, 304
 – tag 362, 363
 allyl ether 350, 361, 363
 allyl indium, addition on unprotected sugars 43
 allyloxy- and benzyloxy-methyl Gignard reagents 38–39
 amide bond 364, 366
 amine-protecting group strategies 163
 – chemoselective amine group manipulations 163–165
 amino acid 364, 366
 aminoethylphosphonate 342
 aminoglycoside acetyl transferases (AACs) 177
 aminoglycoside-modifying enzymes (AMEs) 173, 180
 aminoglycosides 161–163
 – amine-protecting group strategies 163
 – – chemoselective amine group manipulations 163–165
 – amphiphilic aminoglycosides 174–177
 – analogs preparation, and chemoenzymatic strategies 177–179
 – chemoselective alcohol-protecting group manipulations 167, 169–171
 – controlled degradation 165–167
 – natural antibiotics structural diversity 162
 – novel synthetic strategies synthetic strategies to overcome resistance 180–182
 – procedures 182–186
 – scaffolds glycosylation strategies 171–173
 aminosugar library synthesis 7–9
 amphiphilic character 339, 345
 anchored proteins, *See*
 glycosylphosphatidylinositol (GPI) synthesis
 angiogenesis 191
 aniline 76
 anomer 350, 356, 357
 anomeric effect 150, 154
 anthrax tetrasaccharide synthesis 17, 18–21
 antigen presentation 337
 arabinofuranosides 118
 arabinose systems 118
 arabinosides 118
 aromatic-sugar interaction 296, 305
 artificial D-heptosides, as HldE and GmhA inhibitors 54–56
 aryl thioesters 78
 A-site rRNA 161, 173
 asymmetric catalysis 1, 21, 22
 azasugar synthesis 9–10
 azido-glycosides formation 91–92
- ### b
- Bacillus anthracis* 17
 bacterial heptose biosynthetic pathways 53–54
 benzoyl esters 337, 346, 347, 351, 352
 benzyl ethers 345, 346, 347, 351, 352, 356, 359

- benzylsulfonyl group 131
 - bicyclic stabilized cations 127
 - bidirectional iterative Pd-catalyzed glycosylation and postglycosylation 5–7
 - aminosugar library synthesis 7–9
 - binding partners 361
 - biological functions 337
 - biological role 337
 - biological studies 359, 363
 - biosynthesis 335
 - biotinyl hydrazides 71
 - bis(dibutylstannylene)ketals 340
 - bis-hydrazide linkers 71
 - Boc protecting group 128
 - Bölm's procedure 290, 305
 - branched glycan 344, 346
 - general synthetic strategy 357, 359–361
 - *Trypanosoma brucei* VSG GPI synthesis
 - from chalcogenide glycosides of finely tuned reactivity 356–357
 - using glycosyl halides 353–356
 - 3-bromopropenyl esters 43, 44
 - building blocks 338, 339, 340–341, 342, 343, 346, 349, 351, 354, 357, 358, 359, 366
- C**
- C-6-O-acetyl function 107
 - calculated energies of stabilization 135, 136, 140
 - calixarenes 296
 - Campylobacter jejuni* 29, 38, 44, 54
 - cap-tag strategies and temporary fluorine-protecting group additions 229–230
 - cationic amphiphiles 163, 174
 - CD52 340, 352, 364, 365
 - ceramide 313, 319, 349
 - glucosyl ceramide cassette approach 319, 321–323
 - GalNAc-GD1a 323, 325–326
 - GQ1b 323, 324
 - LLG-3 326–329
 - C-galactosides 299, 304
 - chalcogenide glycosides 356–357
 - chemical tag 361, 362, 363
 - chemoselective alcohol-protecting group manipulations 167, 169–171
 - chloroacetyl groups 130, 136, 137, 143, 147
 - cholera toxin (CT) 285
 - interaction 288–289
 - cis-glycosidic linkages construction 97–120
 - 1,2-cis-glycosylation stereocontrol, by remote O-acyl protecting groups 125
 - α -glycosides practical synthesis 135–143
 - opposite stereoselectivity and anchimeric assistance 125, 126–135
 - lack of stereocontrolling effect at equatorial O-4 in 4C_1 conformation 143–145
 - procedures 155–156
 - stabilized bicyclic carbocation 150–154
 - substituents effect at O-6 145–150
 - cleistetrosides 12, 13, 14, 15, 16, 17
 - Cleistopholis glauca* 12
 - Cleistopholis patens* 12
 - cleistrioside 12, 13, 14
 - click reactions 362, 363
 - conformational analysis 150
 - conformations 99, 101, 102, 105, 108, 111, 115, 118
 - convergent approach 339, 356
 - convergent route 339, 343
 - cooperative effect 138, 139
 - Cram chelate model 37
 - Crich's stereoselective β -glycosidation 49–51
 - C-terminus 335, 337, 364, 366, 368
 - cyclodextrin chemistry 241–243
 - bulky reagents for direct modifications 259
 - selective transfer 262–263
 - triphenylphosphine 261–262
 - trityl and derivatives 260–261
 - direct modification capping reagents 250
 - another functionality addition 256
 - double capping 253–254
 - opening of caps 256–259
 - single cap 250–253
 - unsymmetrical caps 254–256
 - experimental procedures 279–280
 - general reactivity 244–245
 - monofunctionalization 247
 - random multifunctionalization and multidifferentiation 249–250
 - reagent use in default 247–248
 - supramolecular inclusion complex 248–249
 - nomenclature of modified cyclodextrins 243–244
 - perfunctionalization of each position 245–247
 - selective deprotections 263
 - diisobutylaluminum hydride (DIBAL-H) as deprotecting agent 263–269
 - second deprotection 269–276
 - third protection 276–278
- cyclohexanediols 290

d

- dendrimers 296
- dendrons 296
- de novo approaches 1–4
 - azasugar synthesis 9–10
 - bidirectional iterative Pd-catalyzed glycosylation and postglycosylation 5–7
 - – aminosugar library synthesis 7–9
 - experiments 22–24
 - medicinal chemistry oligosaccharide synthesis 10–12
 - – anthrax tetrasaccharide synthesis 17, 18–21
 - – tri-and tetrasaccharide library syntheses of natural product 12–17
 - of monosaccharides 4–5
- de novo synthesis 340, 341, 346
- deoxy and bridged cyclodextrins 269, 272–276
- deprotection 223, 225, 226, 228, 229
- desymmetrization 340
- diacylglycerols 335
- dialdoses olefination followed by dihydroxylation 31
 - olefination at C-1 position of hexose 33
 - olefination at C-5 position of pentodialdoses 31–33
 - olefination at C-6 position of hexodialdoses 33–34
- diastereomers 340, 343, 354, 356
- diazomethane 40–41
- dicarboxy-cyclohexane-diols (DCCHD) 290, 292, 295, 296, 305
- differentiation 244, 249–250, 253, 262, 269, 272, 278, 278
- 2,3-dichloro-5,6-dicyano-1,4-benzoquinone 226
- difunctionalization and cyclodextrin capping
 - double capping 253–254
 - single cap 250–253
- digitoxin 86–87
- dihydroxylation 1, 2, 4, 6, 7, 10, 13, 14, 15, 22
- diisobutylaluminum hydride (DIBAL-H), as deprotecting agent
 - application to cyclodextrins 265–269
 - general mechanism 263–265
- α -directing influence 136, 137, 138, 147
- β -directing influence 127, 144
- disialic acid 314, 315, 326
- dithiane 42–43
- divinyl zinc, addition to anomeric lactol 44
- dodecasaccharide retrosynthesis 198

e

- electron-withdrawing group 130, 131, 132, 147, 149
- enzyme-linked immunosorbent assay (ELISA) 70
- Escherichia coli* 53, 285, 287, 289
- ethynyl and vinyl Grignard reagents 36–38
- Eubacterium saburreum* 116, 117
- eukaryotes 337

f

- fatty acid 337, 340, 351, 352, 357
- Ferrier rearrangement 341
- fibroblast growth factor receptor (FGFR) 193, 195, 199, 201, 205, 213
- fibroblast growth factors (FGFs) 193, 195, 199, 201, 203, 205, 213, 214
- flamingo cap 254, 255
- fluorenylmethoxycarbonyl (Fmoc) 228, 229
- fluorescently labeled GPI 362
- fluorination 356
- fluorous-functionalized linkers 83
- fluorous solid-phase extraction (FSPE) 222, 229, 231, 232, 233, 234
 - and fluorous-protecting groups and tags, in carbohydrate synthesis 222
 - – amine protection 224
 - – mono-and diol protecting groups 222–224
 - – phosphate protection 224–226
- fullerene 56, 57
- functionalization, *See also* cyclodextrin chemistry 357, 361, 362, 363, 368

g

- α -galactose 339
- α -galactosides 354
- α -glucosamine 342
- α -glucose 339
- α -glycosides practical synthesis 135–143
- galacturonic acid 105, 107
 - lactones 105, 106
- gangliosides, 11. *See* GM 1 gangliosides; glycosphingolipids (GSLs)
- global deprotection 339, 345, 346, 351, 352, 356, 357, 363
- glucosamine 339, 342, 346, 354
- glucosamines position 2 modifications 201–203
- glycan assembly 338, 346, 352, 357, 361
- glycoblotting 73
- glycolyx 313
- glycoforms 363, 368

- glycolipids 335, 337, 338, 339, 346, 351, 353, 354, 359, 366, 368
 - glycopeptides 340, 364, 365
 - glycopeptides mimics 83, 84
 - glycosaminoglycans (GAGs) 191, 214
 - glycoside 340, 356–357, 361
 - glycosidic bonds 338, 349
 - glycosphingolipids (GSLs) 313–314
 - ceramide moiety synthesis 319
 - experiments 329–331
 - gangliosides complex glycans syntheses 314–315
 - – AG-2 glycan 316, 317–318
 - – GP1c glycan 319
 - – Hp-s6 glycan 315
 - – HPG-7 glycan 315, 316, 317
 - glucosyl ceramide cassette approach 319, 321–323
 - – GalNAc-GD1a 323, 325–326
 - – GQ1b 323, 324
 - – LLG-3 326–329
 - glycosylating agents 341, 342, 346, 356, 359
 - glycosylation 315, 318, 322, 323, 326, 329
 - strategy 341–342
 - glycosyl bromide 354
 - glycosyl fluoride 356
 - glycosyl halides 342, 353–356
 - glycosyl hydrazides (hydrazides)
 - (1-glycosyl)-2-acylhydrazines 79
 - analytical applications 70–73
 - biologically active glycoconjugates 75–77
 - formation tautomeric preference, and stability 68–70
 - hydrazides in synthesis 73–75
 - lectin-labeling strategies using glycosyl hydrazides 77–79
 - glycosyl *n*-pentenyl orthoesters 342
 - glycosyl phosphate formation 92
 - glycosylphosphatidylinositol (GPI) synthesis 335–337
 - branched glycan core
 - – general synthetic strategy 357, 359–361
 - – *Trypanosoma brucei* VSG GPI synthesis from chalcogenide glycosides of finely tuned reactivity 356–357
 - – *Trypanosoma brucei* VSG GPI synthesis using glycosyl halides 353–356
 - challenges 337–339
 - derivatives for biological research 361–363
 - GPI-anchored peptides and proteins 363–364
 - – GPI-anchored cellular prion protein semisynthesis and native chemical ligation 364, 366, 367
 - – skeleton structure of sperm CD52 via direct amide coupling 364, 365
 - linear glycan core
 - – *Plasmodium falciparum*, GPI synthesis via *n*-pentenyl orthoesters 346–348
 - – *Saccharomyces cerevisiae*, GPI synthesis via trichloroacetimidates 349–351
 - – unsaturated GPIs synthesis from *Trypanosoma cruzi* 351–353
 - tools 339
 - – building blocks 340–341
 - – glycosylation strategy 341–342
 - – phosphorylation strategies 342, 343
 - – strategic synthesis planning 343, 344–346
 - glycosylphosphatidylinositol-anchored proteins (GPI-APs) 337
 - glycosyl sulfonylhydrazides 74–75
 - glycosyl trichloroacetimidates 342
 - GM 1 gangliosides 285–286
 - cholera toxin 287–288
 - – interaction 288–289
 - experiments 305–308
 - rational design 289–293
 - – second-generation mimics 293–297
 - third generation mimics 298–304
 - GM2-core 323
 - GP1c glycan 319
 - Grubbs catalyst 201, 215
 - Guillain–Barré Syndrome 323
- ## h
- Haemophilus influenzae* 38–39, 47–48
 - Helicobacter pylori* 115
 - heparan sulfate (HS) 191, 192, 193, 208, 210, 212, 214
 - heparin natural and unnatural fragments 191–193
 - alternative synthetic methods 208
 - – HPN/HS oligosaccharides modular synthesis 210–210, 212
 - – tetrasaccharide mixtures synthesis followed by purification 210
 - biological evaluation 212–214
 - procedures 214–216
 - standard fragments synthesis 193–199
 - synthetic glues 199
 - – aglycon moiety modifications 199–201
 - – glucosamines position 2 modifications 201–203

- O-sulfonation pattern modifications 203–208
 - heptoses 29
 - experiments 58–60
 - heptosides synthesis as biochemical probes 52–53
 - artificial D-heptosides as HldE and GmhA inhibitors 54–56
 - bacterial heptose biosynthetic pathways 53–54
 - Waac heptosyltransferase inhibition studies 56–57
 - heptosylated oligosaccharides synthesis 46
 - bisheptosylated tetrasaccharide synthesis *de novo* approach 51–52
 - *Haemophilus influenzae* 47–48
 - *Neisseria gonorrhoeae* 48–49
 - *Neisseria meningitidis* 46–47
 - *Plesimonas shigelloides* 49–51
 - skeleton construction methods 29–31
 - *de novo* heptose synthesis 44, 45–46
 - dialdoses olefination followed by dihydroxylation 31–34
 - homologation by nucleophilic additions 35–44
 - heptosides synthesis as biochemical probes 52–53
 - artificial D-heptosides as HldE and GmhA inhibitors 54–56
 - bacterial heptose biosynthetic pathways 53–54
 - Waac heptosyltransferase inhibition studies 56–57
 - heterogeneously-promoted β -glycosylation 143, 147, 149
 - hexasaccharide synthesis 195, 197, 202, 205, 212
 - hexodialdoses 33–34
 - hexuronopyranosyl donors 151
 - high-performance (high-pressure) liquid chromatography (HPLC) 226, 229
 - Holothuria pervicax* 315
 - homologation by nucleophilic additions 35
 - elongation at C-1 position of aldose 41–44
 - elongation at C-6 of hexose 35–41
 - homonojirimycin 41, 42
 - Horner–Wittig olefination 34
 - HPG-7 glycan 315, 316, 317
 - H-phosphonates 342, 344, 352
 - Hp-s6 glycan 315
 - hydrogen cyanide 35
 - hydrogenolysis 348, 351, 357, 361, 364, 366
 - hydrogenolytic conditions 345, 351, 356
 - hydrolysis 69, 70, 82, 83, 90, 347, 350, 357, 361, 363
- i**
- immobilization 361
 - immunity 337
 - innate immunity 337
 - inositol 335, 337, 339, 340, 341, 341, 342, 343, 346, 347, 348, 349, 351, 352, 354, 356, 361, 363
 - interleukin 12 (IL-12) 351
 - intrinsic stereoselectivity 150
 - iodine(I) dicollidine perchlorate (IDCP) 138
 - isomerization 350, 361
- k**
- Kiliani reaction 41–42
- l**
- lectin-labeling strategies, using glycosyl hydrazides 77–79
 - L-guluronic acid alginate tetrasaccharide 104
 - light fluorous-tag-assisted synthesis, of oligosaccharides 221–222
 - automated synthesis 232–233
 - cap-tag strategies and temporary fluorous-protecting group additions 229–230
 - carbohydrate microarrays 234
 - double-tagging carbohydrates with fluorous-protecting groups 231
 - experiments 235–237
 - FSPE and fluorous-protecting groups and tags, in carbohydrate synthesis 222
 - amine protection 224
 - mono- and diol protecting groups 222–224
 - phosphate protection 224–226
 - protecting groups with potential use 226
 - alcohol protection 226–227
 - amine protection 228–229
 - carboxylic acid protection 228
 - Linckia laevigata* 326
 - linker 337, 361, 364
 - lipid bilayer 335, 361
 - lipid raft 337
 - lipids 335, 345, 351, 353, 366
 - remodeling 335
 - lipopolysaccharides (LPSs) 29, 351
 - lividomycin A controlled degradation 168
 - LLG-3 ganglioside 326
 - chemical synthesis 326–327, 328
 - chemo-enzymatic synthesis 329

Luche reduction 4, 10, 14, 15
 lyso-alkylglycerol 335

m

macrophages 351
 maltose-binding protein (MBP) 78–79
 mannopeptimycin 10, 11, 12
 β -mannoside 97–98
 mannoside 339, 342, 346, 347, 357
 mannuronic acid 101, 102, 103
 – dodecamer 103
 – donors 99, 101
 matrix-assisted laser desorption/ionization
 mass spectrometry (MALDI-MS) 72, 73
 medicinal chemistry 86–87
 medicinal chemistry oligosaccharide synthesis
 10–12
 – anthrax tetrasaccharide synthesis 17,
 18–21
 – tri- and tetrasaccharide library syntheses of
 natural product 12–17
 membrane anchoring, *See*
 glycosylphosphatidylinositol (GPI) synthesis
 2-methylfuran 35
 methanolysis 351, 352
 methymycin 7–8
 micelle 352
 microarray 362
 – and carbohydrates 234
 molecular mechanics calculations 136
 monoazide cyclodextrins 269
 monofunctionalization 247
 – random multifunctionalization and
 multidifferentiation 249–250
 – reagent use in default 247–248
 – supramolecular inclusion complex
 248–249
 monosaccharide 340, 342, 343, 354, 357
 mucins 76, 351
Mycobacterium avium 141
myo-inositol, *See* inositol
N-alkylhydroxylamines 81

n

naphthyl-functionalized hydrazide 70, 71
 native chemical ligation 364, 366, 367
N-benzyloxyamines 80
 neighboring group participation 351
Neisseria gonorrhoeae 38, 48–49
Neisseria meningitidis 46–47, 51
 neoglycoconjugate 71
 neoglycosylation
 – of digitoxin 86, 87
 – examples 88

neomycin B-based amphiphilic
 aminoglycosides 175
N-linked glycan 364
N, *O*-alkyl-*N*-glycosyl oxyamines 80–83,
 89–90
 – carbohydrate synthesis using
 N-alkyloxyamines 87, 88–89
 – glycobiology 83–85
 – medicinal chemistry 86–87
 – *N*-alkyl-*N*-glycosyloxyamines 83
N, *O*-dialkylamine glycoside 92
 nonhydrolyzable cholera toxin antagonists
 298–304
 Noyori reduction 4, 10
n-pentenyl orthoesters 346–348
 nuclear magnetic resonance (NMR) 221
 nucleotide sugar 53

o

O-alkylation 340, 341
O-alkyl-*N*-glycosyl oxyamines 79
 – formation, configuration, and stability
 79–80
 – uses 80
 octasaccharide 195–196, 202, 208, 209
 oligogalacturonides 69
 oligomannoside 343
 oligonucleotides 342
 oligosaccharide 97, 285, 287, 288, 289, 290,
 296, 304, 335, 340, 342, 344, 366, 367, *See*
 also light fluoros-tag-assisted synthesis of
 oligosaccharides
 – heptosylated oligosaccharides 46
 – – bisheptosylated tetrasaccharide synthesis
 de novo approach 51–52
 – – *Haemophilus influenzae* 47–48
 – – *Neisseria gonorrhoeae* 48–49
 – – *Neisseria meningitidis* 46–47
 – – *Plesimonas shigelloides* 49–51
 – HPN/HS oligosaccharides modular
 synthesis 210, 212
 – medicinal chemistry 10–12
 – – anthrax tetrasaccharide synthesis 17,
 18–21
 – – tri- and tetrasaccharide library syntheses of
 natural product 12–17
Omphalea diandra 41
 one-pot oligosaccharide 229, 230
 optimization 356, 357, 360, 361
 order of assembly 347, 349, 352, 354
 orthoesters 346–348
 orthogonal glycosylation 342, 356, 367
 orthogonal protecting groups 338, 340, 341,
 344, 345, 357, 366

- orthogonal protection 338, 340, 344, 356, 359
- O-sulfonation pattern modifications 203–208
- oxazolidinone 317, 319, 329
- oxidation 342, 343, 347, 351, 352, 356, 357, 361, 363
- oxocarbenium ions 97, 98, 99, 101, 102, 105, 109, 111, 116, 118, 150–154
- P**
- palladium 348, 351, 357, 364
- Pd-catalyzed glycosylation 3, 4, 5–7, 14, 15, 22
 - Pd- π -allyl-catalyzed glycosylation 2, 5, 10, 11, 19, 22
- parasitic protozoa 337
- paromomycin selective O-allylation 171
- participating group 342, 343, 349
- pentafluoropropionyl (PFP) 136, 137, 147
- pentodialdoses 31–33
- pentynoic acid 304
- peptide fragments 335
- peptide sequence 364
- peptide synthesis 364
- perbenzylated cyclodextrins 265–268
- permanent protecting group 339, 345, 346, 351
- permanent protection 345, 351, 352, 359
- permethylated cyclodextrins 268–269
- persilylated cyclodextrins, on primary rim 268
- phosphate 339, 342, 343, 346, 348, 351, 352, 357, 361, 363
- phosphatidylinositol 335
- phosphitylation 342, 343, 347, 351, 352, 356, 357, 361, 363
- phosphoamidites 348, 351, 363
- phosphodiester 335, 338, 339, 343, 344, 349, 353, 354, 356, 359, 360
- phosphoethanolamine 337, 338, 343, 346, 352, 356, 360, 361, 364, 366
- phospholipid 335, 337
- phosphorylation 338, 339, 342–342, 343, 344, 346, 360
- phosphorylation strategies 342, 343
- phytosphingosines 319, 326
- Plasmodium falciparum* and *n*-pentenyl orthoesters 346–348
- Plesiomonas shigelloides* 49–51, 99, 100
- p*-methoxybenzyl (PMB) 346, 347, 352, 356, 363
- poly(ethylene glycol) (PEG)-supported proline 300
- polystyrene resin 364
- posttranslational modification 335
- potentially participating group 125, 127, 139, 144, 145, 150
- preactivation 99, 105, 111
- prión protein 363, 364, 366, 367
- proinflammatory activity 351
- proline catalysis 299, 300
- propargyl glycine 304
- propargyltrimethylsilane 40
- protecting-group-free glycoconjugate synthesis 67–68
- glycosyl hydrazides (hydrazides (1-glycosyl)-2-acylhydrazines 79
 - – analytical applications 70–73
 - – biologically active glycoconjugates 75–77
 - – formation tautomeric preference, and stability 68–70
 - – hydrazides in synthesis 73–75
 - – lectin-labeling strategies using glycosyl hydrazides 77–79
 - *N*, *O*-alkyl-*N*-glycosyl oxyamines 80–83, 89–90
 - – carbohydrate synthesis using *N*-alkyloxyamines 87, 88–89
 - – glycobiology 83–85
 - – medicinal chemistry 86–87
 - – *N*-alkyl-*N*-glycosyloxyamines 83
 - *O*-alkyl-*N*-glycosyl oxyamines 79
 - – formation, configuration, and stability 79–80
 - – uses 80
 - procedures 91–92
- protecting groups 107, 115, 116, 118, 338, 339, 340, 341, 342, 344, 345, 346, 349, 351, 356, 357, 366. *See also* 1,2-*cis*-glycosylation stereocontrol, by remote *O*-acyl protecting groups; light fluororous-tag-assisted synthesis of oligosaccharides
- amine-protecting group strategies 163
 - – chemoselective amine group manipulations 163–165
 - chemoselective alcohol-protecting group manipulations 167, 169–171
- protein glycosylation 363
- protein trafficking 337
- pseudo-GM1 (psGM1) 289, 291, 292, 293, 295, 297, 298
- Pseudomonas aeruginosa* 147, 148
- p*-toluenehydrazide glycosides formation 91
- purification 345, 346, 352, 364

q

quinine 290, 305, 306

r

reactive intermediates 97, 98, 120
 read-through activity, of aminoglycosides 162, 182
 reduction 341, 351, 361, 363
 regioselectivity 253, 255–256, 257, 258, 259, 262, 263, 265, 267, 268, 274, 338, 341, 344, 357
 remote acyl groups 125, 132, 134, 154, 155
 remote anchimeric assistance 125, 127, 128, 136, 147, 150, 152, 154
 resolution 340, 341, 354
 retrosynthetic analysis 347, 349, 352, 354, 359, 366
 reversal, of stereoselectivity 129, 130
 reversible addition–fragmentation chain transfer (RAFT) polymerization 76
 rev response element (RRE) 161

s

Saccharomyces cerevisiae, GPI synthesis via trichloroacetimidates 349–351
 saturation transfer difference 295, 302
 scaffold-replacement approach 293
 β -selectivity 127, 130, 131, 135, 143, 147, 151, 152
 selectivity 244, 245, 256, 259, 260, 265, 267, *See also* cyclodextrin chemistry
 selenoglycosides 356, 357
 semisynthetic aminoglycosides 162, 163, 166, 177, 179, 180
 sialic acid 293–297, 313–314, 315, 316, 317, 319, 329, 339
 sialyl azide 300, 304
 silyl ether 347, 351, 359, 363
 α -silylmethyl Grignard reagents 39–40
 solid-phase peptide synthesis (SPPS) 364
 solid-phase synthesis 102, 103, 112
 solubility 335, 339, 345, 346, 348
 solvent-separated ion pairs (SSIPs) 98
 Sp1 hexasaccharide assembly 110
 sphinganine 319
 sphingoid base 319
 sphingosine 319
 stability 345, 346
 stabilization energies 135, 136, 138, 140
 Staudinger reduction 351
 stereocontrolling effect, of acyl group 126, 137, 143
 – lack 143–145
 stereoselective glycosylation 125, 132, 136

stereoselectivity 97, 98, 99, 101, 102, 105, 107, 109, 111, 113, 114, 115, 116, 117, 118, 339, 341, 343, 349
 strategic synthesis planning 341, 343, 344–346
Streptomyces griseus 161
Streptomyces hygroscopicus 10
Streptomyces venezuelae 7
 structure–activity relationships (SARs) 199, 210, 363
 sulfonium salt 153, 154
 surface plasmon resonance (SPR) 70
 swainsonine 9–10
 synthetic approaches 337, 340, 343
 synthetic convergence 339, 344, 359
 synthetic glues 199
 – aglycon moiety modifications 199–201
 – glucosamines position 2 modifications 201–203
 – O-sulfonation pattern modifications 203–208
 synthetic route 337, 338, 339, 340, 341, 342, 343, 344, 346, 359, 361
 synthetic strategies 180–182, 357, 359–361

t

Tamao–Fleming oxidation conditions 39, 40, 46, 58–60
tert-butoxycarbonyl 228
tert-butyldimethylsilyl (TBS) 207, 346, 352, 354, 357, 363
tert-butyldiphenylsilyl (TBDPS) 147, 205, 207
 tetrabutylammonium fluoride (TBAF) 228
 tetrahydrophthalic anhydride 290
 tetrahydropyranyl (THP) 227
 tetramannoside 349, 350, 351
 tetrasaccharides 204, 211–212
 – mixtures synthesis followed by purification 210–210
 thioester 366
 thioglycoside 342, 356, 357, 363
 tobramycin- and neamine-based amphiphilic aminoglycosides 176
Toxoplasma gondii 361
 tri- and tetrasaccharide library syntheses, of natural product 12–17
 triazole 298, 304
 trifluoroacetic acid (TFA) 199, 201, 228, 352, 357, 363
 trimannoside 350, 363
 2-trimethylsilylthiazole 35

trimethylsilyl trifluoromethanesulfonate
226, 236

triphenylphosphine 261–262

trisaccharides 204

trisialic acid 315, 319

trityl and derivatives 260–261

Trypanosoma brucei 335

– VSG GPI synthesis from chalcogenide
glycosides, of finely tuned reactivity
356–357

– VSG GPI synthesis using glycosyl halides
353–356

Trypanosoma congolense 361

Trypanosoma cruzi 337

tumor necrosis factor (TNF) 351

u

unsaturated fatty acids 351

unsaturated GPIs synthesis from *Trypanosoma*
cruzi 351–353

unsaturated lipids 345, 351, 353

v

variant surface glycoprotein (VSG)
353–357, 361

Vibrio cholerae 285, 289

Vibrio parahaemolyticus 33

virulence 29, 52, 57

w

Waac heptosyltransferase inhibition studies
56–57

weak affinity chromatography (WAC) 299,
300, 301, 304

Wittig reaction 31, 33

Wohl degradation 79

x

Xanthomonas campestris pathovar *campestris*
113–114

y

yeast 349

